SkyePharma Refocuses On Drug Delivery After Drawn-Out Flutiform Development
This article was originally published in The Pink Sheet Daily
With the combination asthma inhaler Flutiform being rolled out across Europe by licensee Mundipharma, the U.K.'s SkyePharma aims now to concentrate on drug delivery research, not clinical development.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.